RxDoctor Payments DataLook up a doctor →

Forrest Swann, MD

Cornea and External Diseases Specialist · Waco, TXNPI 1407291420

Payments from drug & device makers

$111,091in general payments, 2019–2025

Across 645 payments — averaging $172.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$41K
  • Bausch & Lomb Americas Inc.$31K
  • Johnson & Johnson Surgical Vision, Inc.$9K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$9K
  • Carl Zeiss Meditec, Inc.$4K
  • Lensar, Inc.$3K
  • plus $14K from 33 others

What the payments were for

  • Consulting fees$31,65028%
  • Speaking & faculty fees$46,63042%
  • Travel & lodging$7,3217%
  • Food & beverage$25,42923%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,091 in reported general payments places this provider in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.

See all cornea and external diseases specialist providers in Texas

Medicare billing

Part B allowed, 2024
$482,119
Medicare patients
459
Services billed
2,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj34$1,289,391
MieboPerfluorohexyloctane/Pf150$116,078
ProlensaBromfenac Sodium219$76,847
RestasisCyclosporine30$31,570
XdemvyLotilaner13$24,427
Lotemax SmLoteprednol Etabonate80$20,504
VyzultaLatanoprostene Bunod53$19,790
LumiganBimatoprost32$15,842
Bromfenac Sodium79$13,664
Prednisolone Acetate378$12,508
IlevroNepafenac24$8,764
Ofloxacin712$8,226
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat436$6,669
Latanoprost589$5,064
RhopressaNetarsudil Mesylate13$3,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$121$1,289,39134 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$30,848$135,869203 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$8,819$97,351299 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$2,568$53,97494 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$295$24,42713 claims
NovartisIlevro$233$8,76424 claims
Aerie Pharmaceuticals, Inc.Rhopressa$12$3,99013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.

Other cornea and external diseases specialist in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →